Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies.

Mei, Husheng; Wu, Hong; Yang, Jing; Zhou, Bin; Wang, Aoli; Hu, Chen; Qi, Shuang; Jiang, Zongru; Zou, Fengming; Wang, Beilei; Liu, Feiyang; Chen, Yongfei; Wang, Wenchao; Liu, Jing; Liu, Qingsong

Mei, Husheng; Wu, Hong; Yang, Jing; Zhou, Bin; Wang, Aoli; Hu, Chen; Qi, Shuang; Jiang, Zongru; Zou, Fengming; Wang, Beilei; Liu, Feiyang; Chen, Yongfei; Wang, Wenchao; Liu, Jing; Liu, Qingsong.

Afiliação

Mei H; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, 230031, Hefei, Anhui, P. R. China.
Wu H; University of Science and Technology of China, 230026, Hefei, Anhui, P. R. China.
Yang J; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, 230031, Hefei, Anhui, P. R. China.
Zhou B; Hefei Cancer Hospital, Chinese Academy of Sciences, 230031, Hefei, Anhui, P. R. China.
Wang A; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, 230031, Hefei, Anhui, P. R. China.
Hu C; Hefei Cancer Hospital, Chinese Academy of Sciences, 230031, Hefei, Anhui, P. R. China.
Qi S; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, 230031, Hefei, Anhui, P. R. China.
Jiang Z; University of Science and Technology of China, 230026, Hefei, Anhui, P. R. China.
Zou F; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, 230031, Hefei, Anhui, P. R. China.
Wang B; Hefei Cancer Hospital, Chinese Academy of Sciences, 230031, Hefei, Anhui, P. R. China.
Liu F; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, 230031, Hefei, Anhui, P. R. China.
Chen Y; Hefei Cancer Hospital, Chinese Academy of Sciences, 230031, Hefei, Anhui, P. R. China.
Wang W; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, 230031, Hefei, Anhui, P. R. China.
Liu J; Hefei Cancer Hospital, Chinese Academy of Sciences, 230031, Hefei, Anhui, P. R. China.
Liu Q; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, 230031, Hefei, Anhui, P. R. China.

Signal Transduct Target Ther ; 8(1): 18, 2023 01 16.

Article em En | MEDLINE | ID: mdl-36642705

Assuntos

Linfoma Difuso de Grandes Células B; Neoplasias de Mama Triplo Negativas; Humanos; Neoplasias de Mama Triplo Negativas/tratamento farmacológico; Neoplasias de Mama Triplo Negativas/genética; Neoplasias de Mama Triplo Negativas/metabolismo; Linhagem Celular Tumoral; Proteína Potenciadora do Homólogo 2 de Zeste/genética; Proteína Potenciadora do Homólogo 2 de Zeste/metabolismo; Inibidores Enzimáticos; Proliferação de Células/genética; Linfoma Difuso de Grandes Células B/genética; Quinase 4 Dependente de Ciclina

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Neoplasias de Mama Triplo Negativas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Signal Transduct Target Ther Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google